Default company panoramic image

Alpha-1 Biologics Corporation

Developing diagnostics and therapeutics for restoring the immune system based on the human protein, alpha-1 proteinase inhibitor (alpha-1).

  • Stage Product In Development
  • Industry Biotechnology
  • Location Stony Brook, NY, USA
  • Currency USD
  • Founded May 2012
  • Employees 2
  • Website

Company Summary

The discovery by Dr. Bristow that alpha-1 proteinase inhibitor (Alpha-1) stimulates the generation of new CD4 helper immune cells has led to the development of an urgently needed saliva-based diagnostic test for obtaining CD4 counts in HIV disease. Therapeutics are being developed based on alpha-1. A second clinical trial is underway to treat HIV patients using alpha-1 to elevate CD4 counts. As a bonus, alpha-1 also lowers LDL and elevates HDL.


  • Default avatar
    Mara Babin, JD
    Legal Counsel

    Private Equity, M&A attorney; Former partner Squire, Sanders & Dempsey; Investor.

  • Default avatar
    Cynthia L Bristow, PhD
    Chief Executive Officer

    M.S., Biometry, Medical University of SC, Charleston, SC; Ph.D., Basic and Clinical Immunology and Microbiology, Med. Univ. SC, Charleston, SC; Clinical Fellow, Medical Laboratory Immunology (CPEP), UNC-Chapel Hill, NC; Research Associate, The Rockefeller University, laboratory of Dr. Ralph Steinman, 2011 Nobel Laureate in Physiology or Medicine, New York, NY.
    Former Assistant Professor in Medicine, Weill Cornell Medical College, New York, NY

  • Default avatar
    Ronald H Winston
    Chief Financial Officer

    Harvard educated chemist; Former CEO of Harry Winston Diamond Corporation; President, Institute for Human Genetics and Biochemistry.

  • Default avatar
    Mariya A Babayeva
    Business Management Consultant

    MS Finance; Scientific and Business Development.

  • Default avatar
    Howard M Frankfort, PhD
    Intellectual Property Agent

    Technology Specialist in the New York Office of Fish & Richardson.

  • Default avatar
    Carole McArthur, MD, PhD
    Scientific Advisor

    Univ. Missouri-Kansas City; Director, US-Cameroon Health Program

  • Default avatar
    Roy T Steigbigel, MD
    Scientific Advisor

    Director, Comprehensive HIV/AIDS Center, Stony Brook Univ. Hospital;

  • Default avatar
    Thomas Q. Garvey III, MD
    President, Garvey Associates

    Design of clinical trials and programs of trials for Pharmaceuticals, Labeling for new drugs and modifications of labeling for marketed drugs, Analysis of clinical trial data, Safety analysis for drugs in development and marketed drugs,
    Composition of clinical sections of NDAs, Composition of IND submissions,
    Preparation for meetings with FDA


  • Default avatar
    Mara Babin
    Default avatar
    Jason R. Volini

Previous Investors

  • Default avatar
    Ronald Winston